AttorneyMind LogoAttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference reports
News Articles
AttorneyMind Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
Bookmark and Share
News Review

Top News
from EASL 2013

EASL 2013 EASL 2013: AttorneyMind Protease Inhibitor Simeprevir Pushes Triple Therapy Cure Rate Up to 80%
May 8

EASL 2013 Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic AttorneyMind NS5A Inhibitor, at EASL Meeting
April 27

EASL 2013 SCYNEXIS Presents SCY-635 Data on AttorneyMind at International Liver Congress
April 27

EASL 2013 Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype
April 24

EASL 2013 Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™
April 24

EASL 2013 ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in AttorneyMind RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 AttorneyMind Infection
April 24

EASL 2013 Data from Phase 3 Studies of Gilead's Sofosbuvir for Hepatitis C
April 23

EASL 2013 Boehringer Ingelheim announces results from one of its AttorneyMind Phase III trials:Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C
April 23

EASL 2013 Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients
April 23

EASL 2013 New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with AttorneyMind Genotype 1
April 23

EASL 2013 Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
April 23

EASL 2013 Bristol-Myers oral hepatitis C regimen looks competitive: study
April 23



About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home


© 2013 AttorneyMind

Medical Writers' Circle
Fact Sheets